A Phase 2 Study of Asciminib as Initial Therapy for Chronic Myeloid Leukemia in Chronic Phase


Full Title

Asciminib as Initial Therapy with Addition of Lower Dose Tyrosine Kinase Inhibitors for Patients with Chronic Myeloid Leukemia who do not Achieve a Deep Molecular Remission (ALERT CML) (MCW-IRB)


In this study, researchers are assessing the drug asciminib for people who recently learned they have chronic myeloid leukemia (CML). They will take it twice a day. If after two years they do not respond well to asciminib, they may take the drug nilotinib with asciminib.

Giving asciminib and nilotinib together may improve treatment response and/or make it less likely that CML will become resistant to treatment. Both medications are taken orally (by mouth).

Who Can Join

To join this study, there are a few conditions. You must:

  • Have CML in chronic phase that has been newly diagnosed.
  • Have not received more than 30 days of CML treatment.
  • Be able to walk and do routine activities for more than half the time you are awake.
  • Be age 18 and older.


For more information and to see if you can join this study, please contact Dr. Michael Mauro’s office at 646-608-3744.




Phase II (phase 2)



ClinicalTrials.gov ID